Pacific Shuanglin Bio-pharmacy: 2024 Interim Performance Forecast
Pacific Shuanglin Bio-pharmacy: Announcement of Resolutions of the Seventh Meeting (Emergency Meeting) of the Tenth Board of Directors.
Pacific Shuanglin Bio-pharmacy: Announcement regarding the cancellation of expired and unexercised stock options.
Pacific Shuanglin Bio-pharmacy: Legal opinion of Jia Yuan Law Firm, Peking, on the cancellation of the 2020 stock options and restrictive stock incentive plan of Paz Pharmaceutics Co., Ltd. that have expired but not yet exercised.
Pacific Shuanglin Bio-pharmacy: Announcement of the resolution of the Fifth Session of the Tenth Supervisory Board (Emergency Meeting).
Pacific Shuanglin Bio-pharmacy: Announcement on the Implementation of Profit Distribution for the Year 2023.
Pacific Shuanglin Bio-pharmacy: Announcement on the release of pledge of shares by company shareholders.
Pacific Shuanglin Bio-pharmacy: Notice on Wholly-owned Subsidiaries Obtaining Drug Clinical Trial Approval Notice
Pacific Shuanglin Bio-pharmacy: May 20, 2024 Investor Relations Activity Schedule
Pacific Shuanglin Bio-pharmacy: Legal Opinion of Beijing Jiayuan Law Firm on the 2023 Annual General Meeting of Shareholders of Paisi Shuanglin Biopharmaceutical Co., Ltd.
Pacific Shuanglin Bio-pharmacy: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Pacific Shuanglin Bio-pharmacy: Announcement on the completion of the share reduction plan for shareholders holding 5% or more of the shares
Pacific Shuanglin Bio-pharmacy: Announcement on participating in the 2024 Online Investor Group Reception Day for Listed Companies in the Shanxi Region
Pacific Shuanglin Bio-pharmacy: May 7, 2024 Investor Relations Activity Schedule
Pacific Shuanglin Bio-pharmacy: Announcement on Jixi Donghai Pasfike Single Plasma Collection Co., Ltd. obtaining a single plasma collection license
Pacific Shuanglin Bio-pharmacy: Pailin Biotech: Investor Relations Activity Record Form for April 28, 2024
Pacific Shuanglin Bio-pharmacy: 2023 Annual Audit Report
Pacific Shuanglin Bio-pharmacy: Pailin Biotech's 2023 Independent Director Debriefing Report (Zhang Jingang)
Pacific Shuanglin Bio-pharmacy: Pailin Biotech's 2023 Independent Director Debriefing Report (Zhang Yutian has left office)
Pacific Shuanglin Bio-pharmacy: Notice of Annual General Meeting of Shareholders
No Data